Mexico - Delayed Quote MXN

Novartis AG (NVSN.MX)

2,235.00

0.00

(0.00%)

As of March 20 at 12:10:52 PM CST. Market Open.

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 12 hours ago

KHC

PUGBY

PUIGF
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv

TipRanks 10 days ago

LLY

NVS

NVSEF
Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 billion over the next five years to expand its footprint in the U.S. The company said it will establish a research hub in San Diego, expand three U.S. plants and build six new ones. The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis, the company said.

The Wall Street Journal 14 days ago

NVS

NVSEF
Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 billion over the next five years to expand its footprint in the U.S. The company said it will establish a research hub in San Diego, expand three U.S. plants and build six new ones. The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis, the company said.

The Wall Street Journal 14 days ago

NVS

NVSEF
Novartis to spend $23B to expand in the US

Novartis (NVS) announced that it plans to spend $23 billion to expand its manufacturing and research and development facilities in the US. The company says the move will create "approximately 4,000 additional US jobs." To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 14 days ago

NVS

NVSEF
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 16 days ago

DAL

GM

SVNDF
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g1. Vanrafia is a once-daily, non-steroidal, oral treatment that can be added onto supportive care,

PR Newswire 22 days ago

NVS

NVSEF
Big Pharma Avoids Worst-Case Tariff Scenario

Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce. Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.

The Wall Street Journal 22 days ago

JNJ

NVS

NVSEF
Isomorphic raises $600M on big ambitions for AI drugmaking tech

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and predict molecular structures.

BioPharma Dive 25 days ago

NVS
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.

Zacks 25 days ago

AZN

NVS
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of enterprise alignment for our Legal and ERC functions Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis a

GlobeNewswire 25 days ago

NVS

NVSEF
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapyPluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival (rPFS) vs. change in ARPI in Phase III PSMAfore trial*Approximately half of patients do not live long enough to receive a second treatment for mCR

GlobeNewswire 28 days ago

NVS

NVSEF
Here's Why Novartis (NVS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 28 days ago

NVS
5 Large Drug Stocks to Watch as Industry Recovers

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio

Zacks last month

ABBV

PFE

NVS
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravisBasel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcom

GlobeNewswire last month

NVS

NVSEF
Tempero secures $70m to advance addiction treatment candidate

TMP-301 is being investigated in clinical trials for alcohol use disorder and cocaine use disorder.

Pharmaceutical Technology last month

NVS
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks last month

NVS

CNC
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Zacks last month

LLY

MDT

NVS
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s (APLS) Empaveli to differentiate itself. The firm highlights that Fabhalta is indicated for adults with C3G, and is indicated to reduce proteinuria. Moreover, the label explicitly states that outcomes have not been established in post-transplant patients. Morgan Stanley says that overall, the restric

TipRanks last month

NVS

NVSEF

APLS
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition1-4.

PR Newswire last month

NVS

NVSEF

Performance Overview

Return	NVSN.MX	MSCI WORLD (^990100-USD-STRD)
YTD	+14.26%	-3.09%
1-Year	+45.42%	+8.44%
3-Year	+30.62%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NVSN.MX)

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

Novartis to spend $23B to expand in the US

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Big Pharma Avoids Worst-Case Tariff Scenario

Isomorphic raises $600M on big ambitions for AI drugmaking tech

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Here's Why Novartis (NVS) is a Strong Value Stock

5 Large Drug Stocks to Watch as Industry Recovers

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Tempero secures $70m to advance addiction treatment candidate

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Performance Overview